Ceapro Inc.
Ceapro Inc. (CRPOF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
crpof · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Ceapro Inc.You CRPOF | $13M | N/A | — | — |
 Abingdon Health Plc ABDXF | $32M | N/A | — | -$0.01 |
 American Hemp Ventures, Inc. AMHV | $16M | N/A | — | — |
 Eiger BioPharmaceuticals, Inc. EIGRQ | $13M | N/A | — | -$50.78 |
 Living Cell Technologies Limited LVCLY | $11M | N/A | — | -$0.01 |
 Noxopharm Limited NOXOF | $15M | N/A | — | -$0.01 |
 Poxel S.A. PXXLF | $16M | N/A | — | -$0.43 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Ceapro Inc. (CRPOF) measures how much investors pay for each dollar of the company's trailing earnings. CRPOF's current PE ratio of N/A is calculated by dividing its stock price of $0.17 by its TTM earnings per share of —.
Frequently asked questions
CRPOF pe ratio · 6 questionsCRPOF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.17 and TTM EPS of —. Data sourced from Financial Modeling Prep via CRPOF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Ceapro Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09